The Hannibal Clinic Research Center will launch the second phase of a clinical trial in chronic obstructive pulmonary fisease (COPD) and Alpha One Deficiency in August 2018.
“The focus of the second phase of this study is on the immunogenicity of the Alpha One augmentation treatment in patients with deficiency.” said Dr. Humam Farah, Hannibal Clinic board certified pulmonologist.
“The results will not only help patients with COPD and Alpha One deficiency, but will advance our understanding of other disease processes like asthma and bronchiectasis.”
This study will be conducted along with other nationally renowned institutions throughout the United States.
For more information, or to enroll in the study, contact the office of Dr. Humam Farah at 573-231-3767 or Kimber Steinbeck, Ancillary Services manager, at 573-231-3261. Or visit https://clinicaltrials.gov/ct2/show/NCT02525861.
Dr. Farah is a pulmonary critical care and sleep medicine physician. He is a diplomate of the ABIM, holds certification in sleep medicine, critical care medicine, and pulmonary disease.
He graduated from the Faculty of Medicine-University of Jordan. He completed his internship at Dr. Jamil Al-Tutanji Hospital Jordan in 1995. Dr. Farah completed his residency in internal medicine at St. Louis University Hospital in 1999.
Following his residency Dr. Farah completed a fellowship in pulmonary/vritical and dleep medicine at the University of Illinois Chicago.
Hannibal Clinic is a premier multi-specialty medical practice providing excellent healthcare to the residents of Northeast Missouri for over 60 years.
Hannibal Clinic has locations in Hannibal, Palmyra, Monroe City, Center, and Bowling Green with 50 providers on staff in 18 different medical specialties. In providing medical care to the region, Hannibal Clinic also employs over 300 people.